The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 10, 2017

Filed:

Dec. 01, 2015
Applicants:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Washington, DC (US);

The Regents of the University of California, a California Corporation, Oakland, CA (US);

Board of Regents, the University of Texas System, El Paso, TX (US);

Inventors:

Leonard M. Neckers, Bethesda, MD (US);

Marc B. Cox, El Paso, TX (US);

Jane B. Neckers, Bethesda, MD (US);

Yeong Sang Kim, Gaithersburg, MD (US);

Aki Iwai, Toride, JP;

Yangmin Ning, Silver Spring, MD (US);

Johanny Kugelman-Tonos, Frederick, MD (US);

Heather A. Balsiger, El Paso, TX (US);

Robert Fletterick, Hillsborough, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61K 31/192 (2006.01); A61K 31/4741 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); A61K 31/40 (2006.01); A61K 31/4355 (2006.01); A61K 31/195 (2006.01); C07C 233/66 (2006.01); C07C 235/84 (2006.01); C07D 491/048 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4741 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/195 (2013.01); A61K 31/40 (2013.01); A61K 31/4355 (2013.01); A61K 45/06 (2013.01); C07C 233/66 (2013.01); C07C 235/84 (2013.01); C07D 491/048 (2013.01);
Abstract

Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.


Find Patent Forward Citations

Loading…